Liquidia reports preliminary 2025 YUTREPIA net sales of $148.3M; Q4 sales $90.1M

Liquidia Corp

Q4 2025 YUTREPIA net sales ~$90.1M; full-year 2025 net sales ~$148.3M, up 74% QoQ.
Over 2,800 unique patient prescriptions since June 2025 launch; 85% conversion rate (Nov 2025).
Generated >$30M positive cash flow in Q4 2025; cash and equivalents ~$190.7M as of Dec 31.
Plan to expand field sales team in 2026; initiated multiple clinical studies for YUTREPIA and L606.
Preliminary results to be followed by audited full-year financials in Feb 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.